HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.
Τίτλος | HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Kalogiannidis, I., Petousis S., Bobos M., Margioula-Siarkou C., Topalidou M., Papanikolaou A., Vergote I., & Agorastos T. |
Journal | Arch Gynecol Obstet |
Volume | 290 |
Issue | 6 |
Pagination | 1231-7 |
Date Published | 2014 Dec |
ISSN | 1432-0711 |
Λέξεις κλειδιά | Adenocarcinoma, Carcinoma, Endometrioid, Disease-Free Survival, Endometrial Neoplasms, Female, Follow-Up Studies, Greece, Humans, Multivariate Analysis, Neoplasm Grading, Neoplasm Staging, Prognosis, Proportional Hazards Models, PTEN Phosphohydrolase, Receptor, ErbB-2, Survival Rate, Tissue Array Analysis, Treatment Outcome |
Abstract | PURPOSE: To define the prognostic significance of HER-2/neu and PTEN expression in patients with endometrioid (type I) endometrial cancer.METHODS: Seventy-seven patients with endometrioid endometrial carcinoma were included in the study, in a period between 1996 and 2009. Patients with coexisting malignancy and those having incomplete immunohistochemical data or clinical follow-up were excluded. Histological staging was defined according to the revised FIGO staging (2009). Clinico-pathologic and immunohistochemical characteristics were correlated in a multivariate Cox regression analysis with overall survival (OS), cancer-related survival (CRS) and disease-free survival (DFS).RESULTS: Mean age of the patients was 62.7 years. The median follow-up was 67 months (9-124 months). HER-2/neu expression was detected in 18.2 % (n = 14), and PTEN expression in 72.7 % (n = 56) of our patients. Multivariate Cox regression analysis showed that patient's age, FIGO staging and HER-2/neu expression were independent prognostic factors for OS, CRS and DFS. PTEN expression did not significantly affect survival outcomes of the present study.CONCLUSIONS: HER-2/neu but not PTEN expression is an independent prognostic factor for type I endometrial carcinoma. |
DOI | 10.1007/s00404-014-3333-2 |
Alternate Journal | Arch. Gynecol. Obstet. |
PubMed ID | 25022554 |